Table 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri A. Pakola; Katriina Peltola; James H.A. Clubb; Elise Jirovec; Lyna Haybout; Tatiana V. Kudling; Tuomo Alanko; Riitta Korpisaari; Susanna Juteau; Marjut Jaakkola; Jorma Sormunen; Jukka Kemppainen; Annabrita Hemmes; Teijo Pellinen; Mirte van der Heijden; Dafne C.A. Quixabeira; Claudia Kistler; Suvi Sorsa; Riikka Havunen; João M. Santos; Víctor Cervera-Carrascón; Akseli Hemminki

doi:10.1158/1078-0432.26926507.v1

Abstract

Adverse events related to TILT-123 therapy as judged and reported by the investigator, stratified by grade, cohort, and unique patients with reported adverse event.a

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pakola et al. (2024) studied this question.

synapsesocial.com/papers/68e598d9b6db6435875332bf https://doi.org/10.1158/1078-0432.26926507.v1

View Full Paper

Ask AI

Bookmark

Share

Table 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Abstract

Discussion

Cite This Study

Table 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading